Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04603222 · ClinicalTrials.gov registry record · NA

Evaluation of SUMMIT BRUSH in Treatment of Blepharitis

A NA study of Blepharitis, sponsored by University of Notre Dame.

Recruiting
Registry status
NA
Development phase
60
Enrollment target
3
Study locations

NCT04603222: Recruiting NA study of Blepharitis, sponsored by University of Notre Dame.

NCT04603222 is a NA study of Blepharitis that is actively recruiting participants, run by University of Notre Dame. The registered enrollment target is 60 participants, above the 50-participant average among 6 other Blepharitis trials with a reported enrollment target (20% higher). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04603222, a NA study of Blepharitis, is actively recruiting participants, sponsored by University of Notre Dame.

RECRUITING
Registry status
NA
Development phase
60 participants
Enrollment target
3
Study locations

Study Summary

Dry Eye Disease (DED) is a multifactorial disease that affects \~15-30 million people in the USA alone. It creates an enormous societal and economic burden, decreases productivity in the workplace, and affects the quality of lives of the people affected by this disease. DED is primarily caused by blepharitis, a chronic inflammation of the eyelid margins. If left untreated, blepharitis results in the obstruction and loss of the glands responsible for tear film production. The standard of care is the use of self-administered at home commercially available products, e.g., eyelid foams, gels, and pads. Although these products are helpful, they have limitations. Patients often require expensive in office procedures, e.g., lid debridement with exfoliation devices or more expensive procedures. The scope of this project is to evaluate the effectiveness of a new self-administered disposable ocular brush used in conjunction with the most common eyelid cleanser. The investigators are looking to see if combining the microexfoliation provided by the brush with the eyelid cleanser is more effective at removing the eyelid debris than the cleanser alone.

Primary Outcome

Digital photography will be used to asses the eye lid margins pre-treatment, during treatment, and post-treatment. The number of collarettes on the eyelashes will be counted at each visit.

Conditions Studied

Interventions

  • DEVICE SUMMIT BRUSH
  • OTHER Ocusoft Lid Scrub Original Foaming Eyelid Cleanser

Study Locations (3)

Colorado

  • University of Colorado - Boulder

Indiana

  • Michiana Eye Center - Mishawaka

Kentucky

  • Kentucky Eye Institute - Lexington

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2020-07-21
Est. Completion 2022-07-18
Phase NA
University of Notre Dame

13 total trials

What NCT04603222 shows while recruiting

NCT04603222 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, above the 50-participant average among 6 other Blepharitis trials with a reported enrollment target (20% higher).

The record links to 1 condition, with Blepharitis appearing as the primary indexed condition, and to 2 interventions - of which SUMMIT BRUSH is the first listed.

NCT04603222 reports a single indexed study location in Colorado, Indiana, Kentucky.

Frequently Asked Questions

What is clinical trial NCT04603222 about?

NCT04603222 is a clinical study titled "Evaluation of SUMMIT BRUSH in Treatment of Blepharitis". Dry Eye Disease (DED) is a multifactorial disease that affects \~15-30 million people in the USA alone. It creates an enormous societal and economic burden, decreases productivity in the workplace, and affects the quality of lives of the people affected by this disease. DED is primarily caused by bl...

What is the current status of trial NCT04603222?

This trial is currently recruiting. It is a NA study. The enrollment target is 60 participants. The study started on 2020-07-21. Estimated completion is 2022-07-18.

What conditions does trial NCT04603222 study?

This clinical trial studies the following conditions: Blepharitis.

What interventions are being tested in trial NCT04603222?

The interventions under investigation include: SUMMIT BRUSH (DEVICE), Ocusoft Lid Scrub Original Foaming Eyelid Cleanser (OTHER).

Who is sponsoring clinical trial NCT04603222?

This trial is sponsored by University of Notre Dame, which has 13 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04603222 being conducted?

This trial has 3 study locations across Colorado, Indiana, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Blepharitis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00576069 · 60 participants

    Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma

  • NCT01297400 · 60 participants · Phase 2

    Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns

  • NCT01734122 · 60 participants

    Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor

  • NCT01804634 · 60 participants · Phase 2

    Reduced Intensity Haploidentical BMT for High Risk Solid Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04603222, the US trial registry maintained by the National Library of Medicine. NCT04603222 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.